



For immediate release 7.00am: 16 January 2018

**HVIVO PLC**  
("hVIVO" or the "Company")

**Award of Share Options**

hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, announces that on 15 January 2018 it awarded the following options over ordinary shares of 5.0p each in the Company to Liam Eves:

Name	Position	Number of Share Options Awarded	Exercise price per Share	Date of Vesting	Percentage of issued ordinary share capital
Liam Eves	Executive Vice President, Humatics	136,364	5.0p	20 December 2020	0.17%

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail:

**Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them**

<b>1</b>	<b>Details of the persons discharging managerial responsibilities/persons closely associated</b>	
a)	Name	Liam Eves
<b>2</b>	<b>Reason for the notification</b>	
a)	Position/ status	Executive Vice President, Humatics – A person closely associated with Kym Denny, Chief Executive Officer of the Company
b)	Initial notification/ Amendment	Initial Notification
<b>3</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>	
a)	Name	hVIVO plc
b)	Legal Entity Identifier	N/A

<b>4</b>	<b>Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</b>								
a)	<b>Description of the financial instrument, type of instrument</b> Identification code	Options over Ordinary Shares of 5 pence each  ISIN: GB00B6ZM0X53							
b)	Nature of the transaction	Award of options over Ordinary Shares in the Company							
c)	Currency	GBP							
d)	Price(s) and volume(s)	<table border="1"> <thead> <tr> <th>Director</th> <th>Exercise Price (p)</th> <th>Volume</th> </tr> </thead> <tbody> <tr> <td>Liam Eves</td> <td>5.0</td> <td>136,364</td> </tr> </tbody> </table>		Director	Exercise Price (p)	Volume	Liam Eves	5.0	136,364
Director	Exercise Price (p)	Volume							
Liam Eves	5.0	136,364							
e)	Aggregated information  - Aggregated volume  - Exercise price	136,364 options over Ordinary Shares  5.0p							
f)	Date of the transaction	15 January 2018							
g)	Place of the transaction	London Stock Exchange, AIM							

**For further information please contact:**

**hVIVO plc**

+44 207 756 1300

Kym Denny (Chief Executive Officer)

Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries

+1 919 710 9658

Susan Flood (Head of Marketing)

**Numis Securities Limited**

+44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

**FTI Consulting**

Simon Conway / Victoria Foster Mitchell (UK)

+44 203 727 1000

John Capodanno / Evan Smith (US)

+1 212 850 5705

**Notes to Editors:**

hVIVO plc (“hVIVO”), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.